Yüklüyor......
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Myeloproliferative neoplasm (MPN) transformed to acute myeloid leukemia (MPN-AML), MPN in accelerated phase (MPN-AP), and high-risk primary myelofibrosis (PMF) are associated with a poor response to therapy and very short survival. Several reports have suggested clinical activity of hypomethylating...
Kaydedildi:
| Yayımlandı: | Leuk Res |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4546869/ https://ncbi.nlm.nih.gov/pubmed/26183878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.06.001 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|